Dopaminergic News and Research

RSS

Enrollment and dosing in NeuroDerm's Phase I clinical trial of ND0611 completed

NeuroDerm, Ltd. announced today the successful enrollment and dosing in its Phase I clinical trial of ND0611. ND0611, a proprietary drug formula administered via a dermal patch, is designed to maintain continuous therapeutic levodopa concentrations for improving the treatment of Parkinson's disease.

1 Jun 2010

Study: Cell-based strategy for treating neurodegenerative diseases

UCSF scientists have used a novel cell-based strategy to treat motor symptoms in rats with a disease designed to mimic Parkinson's disease.

26 Mar 2010

Turning microRNAs into novel drugs

Researchers around the globe are working on turning microRNAs, over 5,000 of which already have been identified, into novel drugs for a wide range of applications, reports Genetic Engineering & Biotechnology News (GEN). These noncoding single-stranded RNAs act through binding to complementary mRNA sequences, thus preventing their translation into protein or accelerating mRNA breakdown, according to the March 15 issue of GEN.

20 Mar 2010

NeuroSearch's MermaiHD study supports potential Huntington's disease modifying properties of Huntexil

NeuroSearch today announced that further analysis of the data from the MermaiHD study with Huntexil(R) (pridopidine) for the treatment of Huntington's disease supports potential disease modifying properties of the drug.

11 Mar 2010

SRI International establishes new Neurodegenerative Diseases Research Program

SRI International, an independent nonprofit research and development institute, announced today that a new Neurodegenerative Diseases Research Program has been established within its Center for Health Sciences. This new SRI group of neuroscientists and researchers working at the cutting edge of science brings $6.2 million of funding from the National Institutes of Health (NIH), including the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Environmental Health Sciences (NIEHS), and National Institute of General Medical Sciences (NIGMS).

19 Feb 2010

FDA issues Complete Response Letter for Horizant in treatment of RLS

GlaxoSmithKline and XenoPort, Inc. Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS).

18 Feb 2010

New genetic risk factor for Parkinson's disease identified

An international team of doctors and human geneticists has identified a new genetic risk factor for Parkinson's disease. The institutions involved in the study were the Institute of Human Genetics of Helmholtz Zentrum München and Technische Universität München, the Neurological Clinic of Ludwig-Maximilians-Universität Munich (LMU) and the Mitochondrial Research Group of Newcastle University, Newcastle upon Tyne, UK.

18 Jan 2010

Molecules capable of reversing brain abnormalities in PD identified

Scientists identified several molecules capable of reversing the brain abnormalities of Parkinson's disease (PD), while also uncovering new clues for its origin in a study just published in the journal Disease Models and Mechanisms. PD is characterised by abnormal deposits of a brain protein called alpha-synuclein throughout the damaged brain regions, but exactly what they do there is not clear. The fact that their numbers and spreading are associated disease progression has made them, however, a major point of interest in PD research.

18 Jan 2010

Study reveals interaction of genetic and environmental factors in the pathogenesis of Parkinson's disease

"Our study reveals the interaction of genetic and environmental factors such as dietary habits in the pathogenesis of Parkinson's disease," explained Dr. Matthias Elstner of the Neurological Clinic of LMU and Helmholtz Zentrum M-nchen, lead author of the study.

18 Jan 2010

Scientists explore new potential therapies for Parkinson's disease

Following up on their previous work showing the rescue of dopamine neurons by chemicals that interact with the retinoid X receptor (RXR), researchers have now investigated the potential of these chemicals, known as RXR ligands, for the treatment of Parkinson's disease.

11 Dec 2009

Alcoholism may be dependent on IL-1 polymorphisms: Study

Cytokines are small proteins secreted by cells that serve as molecular messengers between cells. Pro-inflammatory cytokines - which function in the immune system - may be involved in alcohol dependence (AD). A study of three polymorphisms of the interleukin-1 gene complex (IL-1) and one of the tumor necrosis factor-alpha (TNFα) has found that IL-1 may directly contribute to AD among Spanish Caucasian males.

21 Sep 2009

Pesticide exposure is linked to Parkinson's disease

Individuals whose occupation involves contact with pesticides appear to have an increased risk of having Parkinson's disease, according to a report in the September issue of Archives of Neurology, one of the JAMA/Archives journals.

15 Sep 2009

Mid-career scientists receive the 2009 Julie Martin Mid-Career Awards in Aging Research

Charleen T. Chu, MD, PhD, associate professor at the University of Pittsburgh and David M. Sabatini, MD, PhD, associate professor, Massachusetts Institute of Technology, received the 2009 Julie Martin Mid-Career Awards in Aging Research. Sponsored by The Ellison Medical Foundation, the grants provide funding of $550,000 to mid-career scientists whose research has great potential in advancing understanding of basic aging and its impact on age-related diseases.

26 Aug 2009

Role of HPRT genes detected in Lesch Nyan X-linked inherited disorders

A study from the Center for Molecular Genetics at the University of California, San Diego School of Medicine shows that a gene called HPRT plays an important role in setting the program by which primitive or precursor cells decide to become normal nerve cells in the human brain. This unconventional view of metabolic genes known as "housekeeping" genes is now online at the journal Molecular Therapy.

21 Aug 2009

Leptin influences baseline dopamine levels and motivation to eat

As we all know from experience, people eat not only because they are hungry, but also because the food just simply tastes too good to pass up. Now, a new study in the August 6th Cell Metabolism, a Cell Press publication, helps to explain how leptin, a hormone produced by fat tissue, influences that motivation to eat.

5 Aug 2009

Merck Serono starts second phase III trial of Safinamide in advanced Parkinson's

Merck Serono announced today the initiation of the SETTLE study. This study will evaluate the efficacy and safety of a dose range of safinamide (50-100 mg once daily) as add-on therapy to a stable dose of levodopa, in mid- to late-stage Parkinson's disease patients with motor fluctuations compared to placebo.

7 May 2009

oct3 protein key to Parkinson's, drug addiction

Scientists have identified a protein that appears not only to be central to the process that causes Parkinson's disease but could also play a role in muting the high from methamphetamine and other addictive drugs.

4 May 2009

Researchers find direct link between bursting activity of midbrain dopamine neurons and behavior

Researchers are one step closer to understanding the neurobiology that allows people to successfully learn motivated behaviors by associating environmental cues with rewarding outcomes, according to a study published yesterday in the Proceedings of the National Academy of Sciences ' online Early Edition.

6 Apr 2009

Non-invasive brain scanning technique may trace development of Parkinson's disease

While finding a biomarker for Parkinson's disease that would let physicians screen for or track its progression remains an elusive goal, a team led by a University of Illinois at Chicago neuroscientist has shown that a non-invasive brain scanning technique offers promise.

24 Mar 2009

Drug being used to improve cognition affects dopamine, suggesting potential for abuse

Preliminary research in healthy men suggests that the narcolepsy drug modafinil, increasingly being used to enhance cognitive abilities, affects the activity of dopamine in the brain in a way that may create the potential for abuse and dependence, according to a study in the March 18 issue of JAMA.

17 Mar 2009

Dopaminergic News and Research

Enrollment and dosing in NeuroDerm's Phase I clinical trial of ND0611 completed

Study: Cell-based strategy for treating neurodegenerative diseases

Turning microRNAs into novel drugs

NeuroSearch's MermaiHD study supports potential Huntington's disease modifying properties of Huntexil

SRI International establishes new Neurodegenerative Diseases Research Program

FDA issues Complete Response Letter for Horizant in treatment of RLS

New genetic risk factor for Parkinson's disease identified

Molecules capable of reversing brain abnormalities in PD identified

Study reveals interaction of genetic and environmental factors in the pathogenesis of Parkinson's disease

Scientists explore new potential therapies for Parkinson's disease

Alcoholism may be dependent on IL-1 polymorphisms: Study

Pesticide exposure is linked to Parkinson's disease

Mid-career scientists receive the 2009 Julie Martin Mid-Career Awards in Aging Research

Role of HPRT genes detected in Lesch Nyan X-linked inherited disorders

Leptin influences baseline dopamine levels and motivation to eat

Merck Serono starts second phase III trial of Safinamide in advanced Parkinson's

oct3 protein key to Parkinson's, drug addiction

Researchers find direct link between bursting activity of midbrain dopamine neurons and behavior

Non-invasive brain scanning technique may trace development of Parkinson's disease

Drug being used to improve cognition affects dopamine, suggesting potential for abuse

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News